MC2's Hsp90 inhibitor shows signs of efficacy in hidradenitis suppurativa

MC2 has early data suggesting a new target may have utility in the increasingly competitive indication of hidradenitis suppurativa.

The Danish biotech announced Wednesday data from a 15-patient Phase IIa study of small molecule Hsp90 inhibitor MC2-32 that showed activity at 16 weeks. Six of 10 patients treated with the once-daily oral therapy met the primary endpoint of HiSCR50, defined as  ≥50% reduction from baseline in the count of abscesses or nodules, with no increase in the number of abscesses or draining fistulas. One of five patients in the placebo group met the threshold. ...